Pharmaceuticals & Biotechnology
Valuation | |
|---|---|
| Market Cap | 68.8 kCr |
| Price/Earnings (Trailing) | 19.73 |
| Price/Sales (Trailing) | 2.04 |
| EV/EBITDA | 9.67 |
| Price/Free Cashflow | 32.77 |
| MarketCap/EBT | 13.27 |
| Enterprise Value | 70.88 kCr |
Fundamentals | |
|---|---|
Growth & Returns | |
|---|---|
| Price Change 1W | -1.6% |
| Price Change 1M | 1% |
| Price Change 6M | 13.2% |
| Price Change 1Y | 4.7% |
| 3Y Cumulative Return | 35.8% |
| 5Y Cumulative Return | 5.1% |
| 7Y Cumulative Return | 7.4% |
| 10Y Cumulative Return | 6.1% |
| Revenue (TTM) |
| 33.73 kCr |
| Rev. Growth (Yr) | 8.6% |
| Earnings (TTM) | 3.48 kCr |
| Earnings Growth (Yr) | 7.6% |
Profitability | |
|---|---|
| Operating Margin | 16% |
| EBT Margin | 15% |
| Return on Equity | 9.95% |
| Return on Assets | 6.63% |
| Free Cashflow Yield | 3.05% |
Cash Flow & Liquidity |
|---|
| Cash Flow from Investing (TTM) | -1.88 kCr |
| Cash Flow from Operations (TTM) | 3.92 kCr |
| Cash Flow from Financing (TTM) | 119.78 Cr |
| Cash & Equivalents | 5.4 kCr |
| Free Cash Flow (TTM) | 1.96 kCr |
| Free Cash Flow/Share (TTM) | 33.69 |
Balance Sheet | |
|---|---|
| Total Assets | 52.55 kCr |
| Total Liabilities | 17.51 kCr |
| Shareholder Equity | 35.03 kCr |
| Current Assets | 28.65 kCr |
| Current Liabilities | 15.5 kCr |
| Net PPE | 13.28 kCr |
| Inventory | 11.19 kCr |
| Goodwill | 636.76 Cr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.14 |
| Debt/Equity | 0.21 |
| Interest Coverage | 11.94 |
| Interest/Cashflow Ops | 9.84 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 4 |
| Dividend Yield | 0.34% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | -0.90% |
Past Returns: Outperforming stock! In past three years, the stock has provided 35.8% return compared to 12.4% by NIFTY 50.
Balance Sheet: Strong Balance Sheet.
Profitability: Recent profitability of 10% is a good sign.
Size: It is among the top 200 market size companies of india.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Smart Money: Smart money has been increasing their position in the stock.
Momentum: Stock has a weak negative price momentum.
Past Returns: Outperforming stock! In past three years, the stock has provided 35.8% return compared to 12.4% by NIFTY 50.
Balance Sheet: Strong Balance Sheet.
Profitability: Recent profitability of 10% is a good sign.
Size: It is among the top 200 market size companies of india.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Smart Money: Smart money has been increasing their position in the stock.
Momentum: Stock has a weak negative price momentum.
Investor Care | |
|---|---|
| Dividend Yield | 0.34% |
| Dividend/Share (TTM) | 4 |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 60.04 |
Financial Health | |
|---|---|
| Current Ratio | 1.85 |
| Debt/Equity | 0.21 |
Technical Indicators | |
|---|---|
| RSI (14d) | 51.8 |
| RSI (5d) | 33.6 |
| RSI (21d) | 47.66 |
| MACD Signal | Sell |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Sell |
| RSI Signal | Hold |
| RSI5 Signal | Hold |
| RSI21 Signal | Hold |
| SMA 5 Signal | Sell |
| SMA 10 Signal |
Updated May 4, 2025
Summary of Aurobindo Pharma's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Aurobindo Pharma's management provided a positive outlook for the future, highlighting several key growth drivers and strategic initiatives. They reported consolidated revenues of Rs.8,286 crores for Q2 FY26, a 6% year-on-year growth, driven by strong performance in the U.S. formulation business and expansion in European and growth market operations. EBITDA for the quarter stood at Rs.1,678 crores, with a margin of 20.3%, marking a 7% increase year-on-year.
Management outlined the following forward-looking points:
Sustained Growth: The company remains confident in maintaining its growth momentum, bolstered by anticipated volume expansion and a stable pricing environment.
European Market: The European business is on track to achieve an annual revenue milestone of €1 billion by the end of FY26, reflecting a revenue growth of 18% year-on-year, amounting to Rs.2,480 crores.
U.S. Operations: The U.S. injectable sales grew by 6% quarter-on-quarter, with new product launches and increasing volumes contributing to the growth. The Dayton facility will commence significant revenue contributions in FY27, with product launches starting in January.
Pen-G Facility: The Pen-G facility operations began on July 1, 2025, with plans to ramp up capacity from 6,000 MT to 15,000 MT quickly, supported by government representation for a minimum import price, essential for profitability.
Biosimilar Pipeline: Several biosimilars are advancing through clinical trials, with submissions to the European Medicines Agency planned for mid-2026.
Margin Targets: Aurobindo aims to achieve an internal margin target of 20%-21% for FY26, with operational excellence and disciplined capital management emphasized.
Overall, Aurobindo Pharma is strategically positioned for growth, with expansion objectives and pipeline advancements across various business segments.
Understand Aurobindo Pharma ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| RPR SONS ADVISORS PRIVATE LIMITED, MRS.P.SUNEELA RANI (JOINTLY HOLDING) | 33.5% |
| K NITYANANDA REDDY | 4.37% |
| KIRTHI REDDY KAMBAM | 3.45% |
| VENKATA RAMPRASAD REDDY PENAKA | 3.07% |
| AXIS CLINICALS LIMITED, TRIDENT CHEMPHAR LIMITED, RPR SONS ADVISORS PVT.LTD. (JOINTLY HOLDING) | 2.85% |
| M SIVAKUMARAN | 2.47% |
Detailed comparison of Aurobindo Pharma against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries | 4.08 LCr | 58.94 kCr | +1.90% | 0.00% | 37.37 | 6.92 | - | - |
| DIVISLAB | Divi's Lab | 1.63 LCr | 10.75 kCr |
Comprehensive comparison against sector averages
AUROPHARMA metrics compared to Pharmaceuticals
| Category | AUROPHARMA | Pharmaceuticals |
|---|---|---|
| PE | 19.08 | 33.87 |
| PS | 1.97 | 4.67 |
| Growth | 6.8 % | 10.8 % |
Aurobindo Pharma is a prominent pharmaceutical company based in Hyderabad, India, with the stock ticker AUROPHARMA.
With a market capitalization of Rs. 72,437.6 Crores, Aurobindo Pharma specializes in the manufacture of generic formulations and active pharmaceutical ingredients (APIs) across several global markets, including India, the USA, Europe, and Puerto Rico. The company provides a wide range of product formulations such as oral solids, liquids, injectables, and vaccines, alongside over-the-counter drugs.
In addition to its formulation offerings, Aurobindo Pharma develops APIs, biosimilars, biocatalysts, peptides, and hormones targeting various therapeutic areas such as the central nervous system, cardiovascular health, respiratory conditions, antibiotics, anti-retrovirals, anti-diabetics, gastroenterology, oncology, and dermatology. Notably, it produces antiretroviral drugs for those living with HIV and offers project-based chemistry contract services for drug lifecycle management, covering both sterile and non-sterile penicillins, cephalosporins, penems, and non-beta lactams.
The company has demonstrated strong financial performance, recording a trailing 12 months revenue of Rs. 31,571.6 Crores and a profit of Rs. 3,488.1 Crores over the past four quarters. Aurobindo Pharma has also shown significant growth, achieving 31.7% revenue growth over the past three years.
In terms of investor returns, Aurobindo Pharma distributes dividends, with a yield of 0.36% annually. In the last year, it purchased back 0.9% of its own stock, contributing positively to its share price. The company was incorporated in 1986 and remains committed to advancing pharmaceutical innovation and production.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
| Sell |
| SMA 20 Signal | Sell |
| SMA 50 Signal | Sell |
| SMA 100 Signal | Sell |
AUROPHARMA vs Pharmaceuticals (2021 - 2026)
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Aurobindo Pharma reported a net profit of Rs 845.81 Crores last quarter.
This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.
Here are the major questions from the Q&A section of the Aurobindo Pharma Q2 FY26 earnings call, along with their respective detailed answers.
1. Question: Are we broadly back to the levels where disruption happened in the U.S. Generic Injectable business, and how do you see this shaping up in the next two years? Can you also discuss some key pipeline products?
Answer: We're not back to pre-disruption levels yet; I believe we need an additional $5-10 million to reach that point. This setback is mostly due to a lack of new products offsetting price declines. But we are optimistic about our pipeline, especially with Eugia III seeking reinspection and approvals, the Vizag plant's new products, and upcoming Oncology oral solids launches expected in Q4 and Q1 next year.
2. Question: What would be the EBITDA loss contribution from the Pen-G plant currently, and at what level do we breakeven?
Answer: We are nearing breakeven as we currently produce around 6,000 tons annually. We can increase it to about 800 tons per month easily, which would positively contribute to EBITDA. Regarding pricing impacts, we need to see policy changes to really determine the effects.
3. Question: Can you discuss any changes in the U.S. pricing erosion trends and how they might affect your business?
Answer: Presently, the price erosion trend remains close to neutral at a low single-digit level, around 1%. While there are opportune moments for pricing increases, we must recognize that when more competitors enter the market, prices typically decrease. Thus, we remain confident but cautious.
4. Question: What is the projected margin trajectory for FY27 and beyond, independent of external factors such as Eugia III's inspection outcome?
Answer: I can provide clearer guidance once we learn about the Pen-G MIP status in the next couple of months. Currently, we expect solid margins driven primarily by the production ramp-up.
5. Question: Regarding Europe, do you believe you can sustain mid-teens growth for the next 2-3 years as you approach the €1 billion milestone?
Answer: Yes, we've now crossed the €1 billion mark in revenues, and our key markets continue to perform well. I am confident about maintaining mid-teens growth moving forward given our recent performance and market position.
6. Question: What are the developments in your biosimilars pipeline, particularly for Denosumab and Omalizumab?
Answer: We successfully completed a Phase 3 trial for Denosumab and plan to submit marketing authorization applications to the EMA by April 2026. For Omalizumab, we're on track for submissions in mid-2026. Significant progress is being made across the biosimilars portfolio.
7. Question: Can you clarify the projected asset turnover for the new China plant over the next few years?
Answer: We expect the China plant to reach breakeven in the first year and aim for triple-digit turnover within the next three years, given the high productivity and favorable margins anticipated.
These responses encapsulate the essence of the questions while providing insights into Aurobindo Pharma's operations and future outlook.
| NPS TRUST A/C - SBI PENSION FUND - UPS - CG SCHEM | 2.23% |
| KAMBAM SPOORTHI | 1.19% |
| K RAJESWARI | 0.31% |
| M SUMANTH KUMAR REDDY | 0.27% |
| TRIDENT CHEMPHAR LIMITED | 0.13% |
| AXIS CLINICALS LIMITED | 0.11% |
| PRASADA REDDY KAMBHAM | 0.05% |
| SUNEELA RANI PENAKA | 0.02% |
| PENAKA NEHA REDDY | 0% |
| K SURYAPRAKASH REDDY | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
| -1.40% |
| +5.20% |
| 65.86 |
| 15.18 |
| - |
| - |
| CIPLA | Cipla | 1.09 LCr | 29.37 kCr | -3.00% | -7.20% | 24.07 | 3.73 | - | - |
| DRREDDY | Dr. Reddy's Lab | 1.06 LCr | 36.09 kCr | +8.00% | +6.00% | 18.98 | 2.94 | - | - |
| LUPIN | Lupin | 1.01 LCr | 26.49 kCr | +2.10% | +12.80% | 21.84 | 3.83 | - | - |
| 4.2% |
| 7,430 |
| 7,132 |
| 6,769 |
| 7,150 |
| 6,938 |
| 6,725 |
| Profit Before exceptional items and Tax | 10.1% | 1,403 | 1,274 | 1,205 | 1,367 | 1,198 | 1,207 |
| Exceptional items before tax | - | -65.33 | 0 | 0 | 0 | 0 | 0 |
| Total profit before tax | 5% | 1,338 | 1,274 | 1,205 | 1,367 | 1,198 | 1,207 |
| Current tax | -17.3% | 383 | 463 | 491 | 431 | 498 | 322 |
| Deferred tax | 221.4% | 45 | -35.24 | -108.12 | 1.75 | -143.79 | 68 |
| Total tax | 0.2% | 429 | 428 | 383 | 432 | 354 | 391 |
| Total profit (loss) for period | 7.3% | 910 | 848 | 824 | 903 | 846 | 817 |
| Other comp. income net of taxes | -58% | 228 | 541 | 406 | 140 | -65.27 | 270 |
| Total Comprehensive Income | -18.1% | 1,138 | 1,389 | 1,230 | 1,042 | 780 | 1,087 |
| Earnings Per Share, Basic | 7.8% | 15.67 | 14.61 | 14.2 | 15.56 | 14.56 | 14 |
| Earnings Per Share, Diluted | 7.8% | 15.67 | 14.61 | 14.2 | 15.56 | 14.56 | 14 |
| 8.4% |
| 1,063 |
| 981 |
| 1,642 |
| 1,600 |
| 1,735 |
| 1,561 |
| Finance costs | 25.8% | 230 | 183 | 115 | 17 | 29 | 96 |
| Depreciation and Amortization | 16.5% | 297 | 255 | 435 | 415 | 488 | 470 |
| Other expenses | 7% | 1,705 | 1,593 | 2,549 | 2,367 | 2,724 | 2,496 |
| Total Expenses | 0.5% | 8,903 | 8,859 | 11,612 | 10,246 | 12,221 | 11,147 |
| Profit Before exceptional items and Tax | -1.9% | 2,358 | 2,403 | 1,614 | 1,712 | 4,193 | 2,378 |
| Exceptional items before tax | - | 0 | 0 | 0 | -74.71 | 0 | 0 |
| Total profit before tax | -1.9% | 2,358 | 2,403 | 1,614 | 1,637 | 4,193 | 2,378 |
| Current tax | 4.9% | 627 | 598 | 407 | 380 | 1,043 | 506 |
| Deferred tax | 82.6% | -15.71 | -95.26 | -23.08 | -196.93 | 37 | -0.9 |
| Total tax | 21.7% | 612 | 503 | 384 | 183 | 1,080 | 505 |
| Total profit (loss) for period | -10.6% | 1,747 | 1,954 | 1,230 | 1,455 | 3,113 | 1,873 |
| Other comp. income net of taxes | -132.7% | -5.26 | -1.69 | 5.87 | 1.69 | -6.42 | -12.55 |
| Total Comprehensive Income | -10.8% | 1,742 | 1,952 | 1,236 | 1,456 | 3,106 | 1,860 |
| Earnings Per Share, Basic | -10.4% | 29.97 | 33.35 | 21 | 24.83 | 53.13 | 31.96 |
| Earnings Per Share, Diluted | -10.4% | 29.97 | 33.35 | 21 | 24.83 | 53.13 | 31.96 |
| 139.1% |
| 209 |
| 88 |
| 115 |
| 133 |
| 79 |
| 239 |
| Goodwill | 0% | 92 | 92 | 92 | 92 | 92 | 92 |
| Non-current investments | 8.1% | 16,436 | 15,210 | 14,204 | 13,393 | 8,397 | 8,222 |
| Loans, non-current | -45.3% | 905 | 1,654 | 1,822 | 1,429 | 2,450 | 2,601 |
| Total non-current financial assets | 2.8% | 17,385 | 16,907 | 16,074 | 14,862 | 10,883 | 10,898 |
| Total non-current assets | 3% | 20,415 | 19,824 | 19,101 | 17,915 | 13,752 | 15,210 |
| Total assets | 1.9% | 28,047 | 27,513 | 26,663 | 25,154 | 26,449 | 24,934 |
| Borrowings, non-current | -55.1% | 180 | 400 | 440 | 0 | 0 | 0 |
| Total non-current financial liabilities | -54.8% | 183 | 404 | 450 | 22 | 32 | 43 |
| Provisions, non-current | 46.2% | 77 | 53 | 48 | 46 | 53 | 87 |
| Total non-current liabilities | -34.8% | 364 | 558 | 611 | 186 | 285 | 346 |
| Borrowings, current | 0.3% | 4,238 | 4,225 | 3,794 | 2,818 | 4,206 | 4,143 |
| Total current financial liabilities | -3.3% | 6,098 | 6,306 | 6,240 | 5,046 | 6,062 | 6,465 |
| Provisions, current | 25% | 26 | 21 | 22 | 18 | 18 | 30 |
| Current tax liabilities | 6.3% | 68 | 64 | 97 | 102 | 49 | 92 |
| Total current liabilities | -2.8% | 6,242 | 6,420 | 6,395 | 5,245 | 6,216 | 6,673 |
| Total liabilities | -5.3% | 6,606 | 6,979 | 7,006 | 5,431 | 7,784 | 7,019 |
| Equity share capital | 0% | 58 | 58 | 58 | 59 | 59 | 59 |
| Total equity | 4.4% | 21,441 | 20,534 | 19,656 | 19,723 | 18,665 | 17,914 |
| Total equity and liabilities | 1.9% | 28,047 | 27,513 | 26,663 | 25,154 | 26,449 | 24,934 |
| 11.1% |
| 669 |
| 602 |
| 301 |
| 692 |
| - |
| - |
| Net Cashflows From Operating Activities | -4% | 1,646 | 1,715 | 1,821 | 3,727 | - | - |
| Cashflows used in obtaining control of subsidiaries | - | 0 | 0 | 169 | 0 | - | - |
| Proceeds from sales of PPE | 1367.4% | 55 | 4.68 | 23 | 643 | - | - |
| Purchase of property, plant and equipment | -41% | 247 | 418 | 354 | 614 | - | - |
| Purchase of intangible assets | -112.3% | 0 | 9.16 | 4.54 | 3.24 | - | - |
| Proceeds from sales of long-term assets | -100% | 0 | 3,895 | 0 | 0 | - | - |
| Cash receipts from repayment of advances and loans made to other parties | -83.4% | 359 | 2,163 | 374 | 363 | - | - |
| Dividends received | -100.4% | 0 | 265 | 165 | 452 | - | - |
| Interest received | -61.8% | 77 | 200 | 80 | 52 | - | - |
| Other inflows (outflows) of cash | 61.8% | 7.91 | 5.27 | 0.08 | 0 | - | - |
| Net Cashflows From Investing Activities | -1184.1% | -2,065.9 | -159.96 | -3,459.68 | -1,613.51 | - | - |
| Payments to acquire or redeem entity's shares | - | 930 | 0 | 0 | 0 | - | - |
| Proceeds from borrowings | - | 1,823 | 0 | 2,287 | 0 | - | - |
| Repayments of borrowings | -97.8% | 30 | 1,342 | 0 | 2,154 | - | - |
| Payments of lease liabilities | 9.5% | 24 | 22 | 21 | 21 | - | - |
| Dividends paid | -100.2% | 0.54 | 264 | 440 | 264 | - | - |
| Interest paid | 5.7% | 222 | 210 | 107 | 8.76 | - | - |
| Net Cashflows from Financing Activities | 133.5% | 616 | -1,837.03 | 1,719 | -2,447.54 | - | - |
| Effect of exchange rate on cash eq. | 103.3% | 16 | 8.38 | 0.48 | -1.03 | - | - |
| Net change in cash and cash eq. | 176.8% | 212 | -273.81 | 81 | -335.37 | - | - |
General • 10 Feb 2026 Intimation of completion of US FDA inspection at Unit VII of the Company at Jedcherla. |
Investor Presentation • 09 Feb 2026 Submission of investor presentation on unaudited financial results for the quarter and nine months period ended December 31, 2025. |